Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of Keytruda in high-grade HPV-related vulvar and cervical premalignant lesions
2019-002247-23Phase 2Active
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cervical intraepithelial neoplasia (CIN) and vulvar intraepithelial neoplasia (VIN), sponsored by Policlinico Gemelli. Primary endpoint: Histopathologic complete regression of cervical HSIL. Started Jun 2021; status: active.
02
Drugs
03
Conditions
cervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2019-002247-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002247-23.